Pollak M - Search Results

1

Integrated Pharmacodynamic Analysis Identifies Two Metabolic Adaption Pathways to Metformin in Breast Cancer.

Lord SR, Cheng WC, Liu D, Gaude E, Haider S, Metcalf T, Patel N, Teoh EJ, Gleeson F, Bradley K, Wigfield S, Zois C, McGowan DR, Ah-See ML, Thompson AM, Sharma A, Bidaut L, Pollak M, Roy PG, Karpe F, James T, English R, Adams RF, Campo L, Ayers L, Snell C, Roxanis I, Frezza C, Fenwick JD, Buffa FM, Harris AL. Lord SR, et al. Among authors: pollak m. Cell Metab. 2018 Nov 6;28(5):679-688.e4. doi: 10.1016/j.cmet.2018.08.021. Epub 2018 Sep 20. Cell Metab. 2018. PMID: 30244975 Free PMC article. Clinical Trial.

2

Potential role for somatostatin analogues in breast cancer: rationale and description of an ongoing trial.

Pollak M, Gallant K, Poisson R, Harris A. Pollak M, et al. Metabolism. 1992 Sep;41(9 Suppl 2):119-20. doi: 10.1016/0026-0495(92)90045-c. Metabolism. 1992. PMID: 1355585 Clinical Trial.

3

Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells.

Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. Zakikhani M, et al. Among authors: pollak m. Cancer Res. 2006 Nov 1;66(21):10269-73. doi: 10.1158/0008-5472.CAN-06-1500. Epub 2006 Oct 23. Cancer Res. 2006. PMID: 17062558

4

Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells.

Zakikhani M, Blouin MJ, Piura E, Pollak MN. Zakikhani M, et al. Among authors: pollak mn. Breast Cancer Res Treat. 2010 Aug;123(1):271-9. doi: 10.1007/s10549-010-0763-9. Epub 2010 Feb 5. Breast Cancer Res Treat. 2010. PMID: 20135346

5

Metformin and other biguanides in oncology: advancing the research agenda.

Pollak M. Pollak M. Cancer Prev Res (Phila). 2010 Sep;3(9):1060-5. doi: 10.1158/1940-6207.CAPR-10-0175. Epub 2010 Sep 1. Cancer Prev Res (Phila). 2010. PMID: 20810670 Free PMC article. Review.

6

Metformin abolishes increased tumor (18)F-2-fluoro-2-deoxy-D-glucose uptake associated with a high energy diet.

Mashhedi H, Blouin MJ, Zakikhani M, David S, Zhao Y, Bazile M, Birman E, Algire C, Aliaga A, Bedell BJ, Pollak M. Mashhedi H, et al. Among authors: pollak m. Cell Cycle. 2011 Aug 15;10(16):2770-8. doi: 10.4161/cc.10.16.16219. Epub 2011 Aug 15. Cell Cycle. 2011. PMID: 21811094

7

IGF1/insulin receptor kinase inhibition by BMS-536924 is better tolerated than alloxan-induced hypoinsulinemia and more effective than metformin in the treatment of experimental insulin-responsive breast cancer.

Dool CJ, Mashhedi H, Zakikhani M, David S, Zhao Y, Birman E, Carboni JM, Gottardis M, Blouin MJ, Pollak M. Dool CJ, et al. Among authors: pollak m. Endocr Relat Cancer. 2011 Nov 14;18(6):699-709. doi: 10.1530/ERC-11-0136. Print 2011 Dec. Endocr Relat Cancer. 2011. PMID: 21946410

8

Investigating metformin for cancer prevention and treatment: the end of the beginning.

Pollak MN. Pollak MN. Cancer Discov. 2012 Sep;2(9):778-90. doi: 10.1158/2159-8290.CD-12-0263. Epub 2012 Aug 27. Cancer Discov. 2012. PMID: 22926251 Review.

9

The use of metformin and colorectal cancer incidence in patients with type II diabetes mellitus.

Smiechowski B, Azoulay L, Yin H, Pollak MN, Suissa S. Smiechowski B, et al. Cancer Epidemiol Biomarkers Prev. 2013 Oct;22(10):1877-83. doi: 10.1158/1055-9965.EPI-13-0196. Epub 2013 Aug 21. Cancer Epidemiol Biomarkers Prev. 2013. PMID: 23966577

10

Metformin's potential in oncology.

Pollak M. Pollak M. Clin Adv Hematol Oncol. 2013;11(9):594-5. Clin Adv Hematol Oncol. 2013. PMID: 24518524 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

851 results

Search Page